- Home
- LYEL vs FENC Comparison
LYEL vs FENC Comparison
Compare LYEL & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- FENC
- Stock Information
- Founded
- LYEL 2018
- FENC 1996
- Country
- LYEL United States
- FENC United States
- Employees
- LYEL N/A
- FENC N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LYEL Health Care
- FENC Health Care
- Exchange
- LYEL Nasdaq
- FENC Nasdaq
- Market Cap
- LYEL 207.7M
- FENC 222.9M
- IPO Year
- LYEL 2021
- FENC 2001
- Fundamental
- Price
- LYEL $11.02
- FENC $7.84
- Analyst Decision
- LYEL Sell
- FENC Strong Buy
- Analyst Count
- LYEL 2
- FENC 2
- Target Price
- LYEL $15.00
- FENC $13.00
- AVG Volume (30 Days)
- LYEL 72.8K
- FENC 52.0K
- Earning Date
- LYEL 08-11-2025
- FENC 08-12-2025
- Dividend Yield
- LYEL N/A
- FENC N/A
- EPS Growth
- LYEL N/A
- FENC N/A
- EPS
- LYEL N/A
- FENC N/A
- Revenue
- LYEL $65,000.00
- FENC $30,912,000.00
- Revenue This Year
- LYEL N/A
- FENC $0.85
- Revenue Next Year
- LYEL N/A
- FENC $55.16
- P/E Ratio
- LYEL N/A
- FENC N/A
- Revenue Growth
- LYEL N/A
- FENC N/A
- 52 Week Low
- LYEL $7.65
- FENC $3.96
- 52 Week High
- LYEL $32.60
- FENC $9.30
- Technical
- Relative Strength Index (RSI)
- LYEL 52.37
- FENC 36.52
- Support Level
- LYEL $9.11
- FENC $8.41
- Resistance Level
- LYEL $14.18
- FENC $8.94
- Average True Range (ATR)
- LYEL 0.94
- FENC 0.35
- MACD
- LYEL 0.15
- FENC -0.11
- Stochastic Oscillator
- LYEL 38.68
- FENC 0.00
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.